• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

Although substantial progress has been made in the diagnosis and treatment of acute
coronary syndromes, cardiovascular disease remains the leading cause of death globally …

CYP2C19 catalyzes the bioactivation of the antiplatelet prodrug clopidogrel, and CYP2C19
genotype impacts clopidogrel active metabolite formation. CYP2C19 intermediate and poor …

Antiplatelet therapy is key to reducing local thrombotic complications and systemic
ischaemic events among patients undergoing percutaneous coronary interventions (PCI) …

Importance After percutaneous coronary intervention (PCI), patients withCYP2C19* 2or*
3loss-of-function (LOF) variants treated with clopidogrel have increased risk of ischemic …

always refer to the full text version, which is freely available on the ESC and EACTS
websites. The National Societies of the ESC are encouraged to endorse, translate, and …

Background Whether guided selection of antiplatelet therapy in patients undergoing
percutaneous coronary intervention (PCI) is effective in improving outcomes compared with …

Dual-antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor inhibitor is the standard
treatment for patients undergoing percutaneous coronary intervention. The availability of …

Cardiovascular diseases (CVDs) are the leading cause of premature death and disability in
humans and their incidence is on the rise globally. Given their substantial contribution …

Guidelines, Aspirin, Clopidogrel, Ticagrelor, Prasugrel, Dual antiplatelet therapy, Acute
coronary syndromes, Coronary artery bypass grafting, Coronary artery disease, Drug-eluting …